Archives
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2018-07
-
The initial hyperproliferation phase during crypt regenerati
2022-09-24

The initial hyperproliferation phase during crypt regeneration is reminiscent of the effects of Apc loss during tumour initiation and genetic studies show Yap and Taz are also required for adenoma formation in mice [10••, 12•, 13]. Furthermore, Yap activation by Mst1/2 or Sav deletion increases cry
-
Cut proteins have five evolutionarily conserved
2022-09-23

Cut proteins have five evolutionarily conserved domains. These include a homeodomain, three Cut repeats, and a coiled coil structure. The cut repeats, called CR1, CR2, and CR3, are composed of 70 amino acids, and, along with the homeodomain, are each capable of binding DNA. Mammalian cut proteins fu
-
There are five subfamilies of
2022-09-22

There are five subfamilies of P-type ATPases (I-V), which transport metal ions or phospholipids across membranes (Palmgren and Nissen, 2011). Although our studies indicate that the P-type ATPase domain is important for function, how it contributes to cGMP production is currently unknown. The P-type
-
It has been proposed that HCA may be a better
2022-09-22

It has been proposed that HCA1 may be a better target than HCA2 to treat dyslipidemia and to prevent progression of atherosclerosis, because HCA1 is less widely expressed, and HCA1 activation does not result in flushing. However, since the antilipolytic effects mediated by HCA2 appear to be not the
-
SCR7 Introduction Non alcoholic hepatic steatosis is charact
2022-09-22

Introduction Non-alcoholic hepatic steatosis is characterized by the presence of steatosis in hepatocytes [1], which leads to the development of fatty liver [2]. It is strongly associated with obesity, insulin resistance, and type II diabetes [3]. They are major risk factors of non-alcoholic hepati
-
Previously we have shown that the natural flavonoid compound
2022-09-21

Previously, we have shown that the natural flavonoid compounds that possess C-4 ketone group and C-5 hydroxy group, such as baicalein, luteolin, myricetin and quercetin, effectively inhibit human GLO I. Considering our interest in inhibitors of GLO I and based on the rationale mentioned above, struc
-
The effects of GHS R a blockade on alcohol
2022-09-21

The effects of GHS-R1a blockade on alcohol-related outcomes have been examined in numerous preclinical experiments, utilizing various GHS-R1a antagonists (JMV 2959, [D-Lys3]-GHRP-6, BIM 28163) and rodent species (prairie vole, mouse, rat). In spite of methodological differences, the results consiste
-
The mechanism by which Piezo acts in the regulation of
2022-09-21

The mechanism by which Piezo1 acts in the regulation of RBC volume is not firmly established. Its curved structure implies that it is activated by an increase in membrane tension (11), a mechanism indicated by electrophysiological measurements (16). However, the RBC membrane mechanics at its physiol
-
Lenvatinib is an orally available multi targeted tyrosine
2022-09-21

Lenvatinib is an orally available, multi-targeted tyrosine kinase inhibitor against VEGFR1–3, FGFR1–4, PDGFRα, RET, and KIT [11,12]. In a recent phase III trial for patients with previously untreated uHCC (REFLECT study), lenvatinib showed statistical non-inferiority of overall survival compared to
-
br Introduction The fibroblast growth factor receptor FGFR p
2022-09-21

Introduction The fibroblast growth factor receptor (FGFR) pathway is an important oncogenic driver in malignant cancer. It controls cellular processes such as cell proliferation, differentiation, migration, PAC-1 progression, metabolism, and survival. In non–small-cell lung cancer, the most freq
-
The iAs mainly metabolized in
2022-09-21

The iAs mainly metabolized in the liver to generate MMA and DMA. DMA, MMA and iAs were excreted through the urine (Khaleghian et al., 2014; Wei et al., 2017a). Pearson correlation coefficient was used to explore associations between concentrations of three arsenic species in urine and gene expressio
-
Recent efforts have also tried
2022-09-21

Recent efforts have also tried to identify cancer subsets that are exquisitely responsive to EZH2i apart from those bearing EZH2 gene mutation (Knutson et al., 2012). The dysfunction of SWI-SNF complex, a chromatin-remodeling regulator that partially antagonizes the catalytic function of PRC2 comple
-
br Materials and methods br Results br Discussion Type I
2022-09-20

Materials and methods Results Discussion Type I ECa is associated with estrogen excess, obesity and hormone-receptor positivity. However, the function of ERα on ECa is considered complicated. The expression of ERα is reduced in grade III ECa clinical samples [13]. The high ERα expression is
-
CD 1530 br The HDC knockout mouse as a pathophysiological mo
2022-09-20

The HDC knockout mouse as a pathophysiological model of TS The implication of a hypomorphic allele of the Hdc gene as a rare cause of TS (Ercan-Sencicek et al., 2010) created a rare opportunity for the generation of a pathophysiologically grounded model of the disorder. Modeling pathophysiology o
-
br Neurodystrophic effects of HO It is well
2022-09-20

Neurodystrophic effects of HO-1 It is well known that neonatal hyperbilirubinemia (jaundice) may lead to irreversible neurological injury in children (kernicterus). This outcome can be prevented by photodegradation of circulating bilirubin or treatment with metalloporphyrin inhibitors of HO enzym
15502 records 412/1034 page Previous Next First page 上5页 411412413414415 下5页 Last page